- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04961476
Use of 1-MNA to Improve Exercise Tolerance and Fatigue in Patients After COVID-19
July 14, 2021 updated by: Michal Chudzik
Coronavirus disease 2019 (COVID-19) is a serious respiratory disease that results from infection with a newly discovered coronavirus (SARS-COV-2).
Unfortunately, COVID-19 is not only a short-term infection but that patients (pts) recovering from SARS-COV2 infection complain of persisting symptoms including: fatigue, diffuse myalgia and weakness, which may lead to chronic fatigue syndrome.
There is currently no evidence that nutritional supplements and/or physical exercise can assist in the recovery of pts with chronic fatigue syndrome.
1-Methylnicotinamide (1-MNA) is an endogenic substance that is produced in the liver when nicotinic acid is metabolized.
1-MNA demonstrates anti-inflammatory and anti-thrombotic properties.
Therefore, we investigated whether 1-MNA supplements could improve exercise tolerance and decrease fatigue among patients recovering from SARS-COV-2.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The study population was composed of pts after COVID-19, expressing subjective feelings of limited tolerance to exercise.
The selected pts were randomized into two groups: GrM0 - without supplementation; GrM1 - with 1-MNA supplementation.
At the beginning of the study (Phase 0), in both groups, a 6-minute walk test (6MWT) was carried out and fatigue assessment with Fatigue Severity Scale (FSS) was performed.
After 1 month (Phase 1), a fol-low up FSS and 6MWT once more were performed in both groups.
Study Type
Observational
Enrollment (Actual)
50
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Łódź, Poland, 90-302
- Medical Center, Saint Family Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Patients after COVID-19, expressing subjective feelings of limited tolerance to exercise and above 50% greater fatigue compared to their pre-COVID-19 levels.
These symptoms must have continued for at least four weeks since the last symptoms of infection.
Description
Inclusion Criteria:
- Patients after COVID-19
- Patients expressing subjective feelings of limited tolerance to exercise and above 50% greater fatigue compared to their pre-COVID-19 levels (symptoms must have continued for at least four weeks since the last symptoms of infection)
Exclusion Criteria:
- Patients with cardiological complications
- Patients with pulmonological complications
- Patients with Chronic Obstructive Pulmonary Disease and/or asthma
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
GrM0
GrM0 - without supplementation
|
|
GrM1
GrM1 - with 1-MNA supplementation
|
1-MNA supplementation
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
6MWT
Time Frame: 1 Month
|
6-Minute Walk Test - Walking distance in meters in 6-minute walk test
|
1 Month
|
FSS
Time Frame: 1 Month
|
Fatigue Severity Scale - a self-administered questionnaire for assessing the severity of fatigue in different situations over the past week.
Each item is rated on a scale from 1 to 7, where 1 indicates strong disagreement and 7 strong agreement.
|
1 Month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 8, 2021
Primary Completion (Actual)
March 5, 2021
Study Completion (Actual)
March 5, 2021
Study Registration Dates
First Submitted
July 12, 2021
First Submitted That Met QC Criteria
July 12, 2021
First Posted (Actual)
July 14, 2021
Study Record Updates
Last Update Posted (Actual)
July 21, 2021
Last Update Submitted That Met QC Criteria
July 14, 2021
Last Verified
July 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Central Nervous System Diseases
- Nervous System Diseases
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Disease
- Musculoskeletal Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Encephalomyelitis
- COVID-19
- Syndrome
- Fatigue
- Fatigue Syndrome, Chronic
Other Study ID Numbers
- Stop-Covid/1/2020
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
Clinical Trials on 1-MNA
-
Montreal Heart InstituteInstitut de Recherches Cliniques de Montreal; Royal Victoria Hospital, Canada; Queen Elizabeth II Health Sciences Centre and other collaboratorsCompletedHypertriglyceridemiaCanada
-
SkinJect, Inc.Terminated
-
University GhentUniversity Hospital, Ghent; Universitair Ziekenhuis Brussel; Vrije Universiteit... and other collaboratorsCompletedChronic Low Back Pain | Chronic Neck Pain | Insomnia ChronicBelgium
-
Cortria CorporationCompleted
-
Pharmena North AmericaCompletedHyperlipidemiaUnited States
-
Prince of Songkla UniversityRecruitingCardiac Surgery | Postoperative Pulmonary Complication | Elderly Patient | Nutrition Scoring SystemThailand
-
Cortria CorporationCompletedHyperlipidemia
-
Cortria CorporationPPD; Pharmena North AmericaCompleted
-
SkinJect, Inc.Active, not recruitingBasal Cell CarcinomaUnited States
-
Fondazione Don Carlo Gnocchi OnlusNot yet recruiting